* Says price of potential acquisitions has increased, prompting company to “go upstream” for early stage drug acquisitions

* Jimenez says Entresto on track for the objectives for the year, expects growth quarter-by-quarter

* Jimenez says timing of Novartis’s involvement in Turkey campaign was unfortunate, but principle of supporting patients around the world remains, declined to comment on plans for campaign Source text for Eikon: Further company coverage: (Reporting by John Miller)